NGM

NGM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.13
-0.16
-0.83%
After Hours: 19.13 0 0.00% 16:00 07/10 EDT
OPEN
19.29
PREV CLOSE
19.29
HIGH
19.61
LOW
18.99
VOLUME
174.67K
TURNOVER
--
52 WEEK HIGH
23.95
52 WEEK LOW
8.81
MARKET CAP
1.30B
P/E (TTM)
-23.5070
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NGM stock price target is 31.00 with a high estimate of 40.00 and a low estimate of 26.00.

EPS

NGM News

More
NGM Biopharmaceuticals initiated at buy with $40 price target at Chardan
marketwatch.com · 3d ago
Were Hedge Funds Right About Warming Up To NGM Biopharmaceuticals, Inc. (NGM)?
Insider Monkey · 5d ago
Intercept Pharmaceuticals: Regulatory Snub Unsettles Liver Therapy Front-Runner
Seeking Alpha - Article · 5d ago
NGM Biopharmaceuticals (NGM) Soars: Stock Adds 7.8% in Session
Zacks · 06/18 13:50
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
NGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/12 18:56
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
GlobeNewswire · 06/08 13:00
Intercept Pharmaceuticals: Undervalued Ahead Of An Eventful Period
Seeking Alpha - Article · 06/07 07:12

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About NGM

NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company’s product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.
More

Webull offers kinds of NGM Biopharmaceuticals Inc stock information, including NASDAQ:NGM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NGM stock methods without spending real money on the virtual paper trading platform.